Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma
Glioblastoma multiforme (GBM), the most common primary brain tumor in adults, is almost never curable with the current standard treatment consisting of surgical resection, irradiation and temozolomide. The prognosis remains poor despite undisputable advances in the understanding of this tumor’s mole...
Main Authors: | Marc-Eric Halatsch, Christian Rainer Wirtz, Richard Eric Kast, Andrej Pala, Georg Karpel-Massler |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2012-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/4/2/523 |
Similar Items
-
Ribozyme-Mediated Inhibition of 801-bp Deletion-Mutant Epidermal Growth Factor Receptor mRNA Expression in Glioblastoma Multiforme
by: Georg Karpel-Massler, et al.
Published: (2010-06-01) -
EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment
by: Stefanie Keller, et al.
Published: (2017-06-01) -
Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma
by: Emily ePadfield, et al.
Published: (2015-01-01) -
Lycorine inhibits glioblastoma multiforme growth through EGFR suppression
by: Jia Shen, et al.
Published: (2018-07-01) -
Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells
by: Xingmei Zhang, et al.
Published: (2018-03-01)